Misoprostol (Synonyms: SC 29333) |
Katalog-Nr.GC16074
One-Click Copy Product Info
|
Misoprostol (SC-29333) ist ein oral aktives synthetisches Prostaglandin E1 (PGE1)-Analogon, das fÜr die Erforschung von MagengeschwÜren verwendet wird.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 59122-46-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Misoprostol is an orally active prostaglandin E1 (PGE1) analog used to prevent gastric ulcers, treat missed abortion, induce labor and induce miscarriage[1, 2]. Misoprostol is used to prevent gastric ulcers induced by nonsteroidal anti-inflammatory drugs. It can bind to prostaglandin receptors and directly act on parietal cells to inhibit gastric acid secretion[3].
In vitro, Misoprostol (10μM) pretreatment of human peripheral blood mononuclear cells (PBMC) and RAW264.7 cells for 90min significantly increased the phosphorylation of cAMP response element binding protein (CREB) in cells[4]. Misoprostol (10μM) treatment of HCT-116 cells for 2h significantly activated intracellular protein kinase A (PKA)[5]. Misoprostol (8ng/mL) treatment of 3D cultured annular cells significantly increased the epidermal growth factor (EGF) level of cells[6].
In vivo, oral administration of Misoprostol (0.2mg/kg/day) to rats with doxorubicin-induced cardiac injury for 6 days alleviated cardiac injury in rats, significantly reduced serum cardiac troponin-I (cTn-I) and brain natriuretic peptide (BNP) levels, and reduced lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatine kinase isoenzyme-MB (CK-MB) activities[7].
References:
[1] Ahmed T A, Mohammed A H. Brief Overview About Prostaglandins & Misoprostol For Cervical Ripening[J]. Journal of Pharmaceutical Negative Results, 2023, 14(2).
[2] Chong Y S, Su L L, Arulkumaran S. Misoprostol: a quarter century of use, abuse, and creative misuse[J]. Obstetrical & gynecological survey, 2004, 59(2): 128-140.
[3] Sostres C, Lanas A. Prostaglandins and other mucosal protecting agents[J]. Pocket Guide to Gastrointestinal Drugs, 2014: 44-56.
[4] Gobejishvili L, Ghare S, Khan R, et al. Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease[J]. Clinical Immunology, 2015, 161(2): 291-299.
[5] Field J T, Martens M D, Mughal W, et al. Misoprostol regulates Bnip3 repression and alternative splicing to control cellular calcium homeostasis during hypoxic stress[J]. Cell Death Discovery, 2018, 4(1): 98.
[6] Gruber H E, Hoelscher G, Loeffler B, et al. Prostaglandin E1 and misoprostol increase epidermal growth factor production in 3D-cultured human annulus cells[J]. The Spine Journal, 2009, 9(9): 760-766.
[7] Bilgic S, Ozgocmen M, Ozer M K, et al. Misoprostol ameliorates doxorubicin induced cardiac damage by decreasing oxidative stress and apoptosis in rats[J]. Biotechnic & Histochemistry, 2020, 95(7): 514-521.
| Cell experiment [1]: | |
Cell lines | Human peripheral blood mononuclear cells (PBMCs)、RAW264.7 cells |
Preparation Method | Cells were plated at 0.5 million/mL density, treated with 10μM Misoprostol for 90min and further stimulated with LPS, 100ng/mL. PKA inhibitor, H89 was used at 10μM concentration 30min before Misoprostol treatment. Nuclear extracts were subjected to Western blot analysis. |
Reaction Conditions | 10μM; 90min |
Applications | Misoprostol exposure resulted in increased phosphorylation of cAMP response element-binding protein (CREB) in both PBMCs and RAW cells; pretreatment with PKA inhibitor, H89 prevented Misoprostol effect on CREB phosphorylation. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Divided the rats randomly into three groups of seven: group 1, control; group 2, Doxorubicin; group 3, Doxorubicin+ MP. The control group was injected intraperitoneally (i.p.) with 0.5mL 0.9% NaCl and given 1mL 0.9% NaCl orally for 6 days. The Doxorubicin group was injected i.p. with a single dose of 20mg/kg Doxorubicin on the third day of the study. The Doxorubicin+Misoprostol group was injected i.p. with a single 20mg/kg dose of Doxorubicin on day 3 of the study and given 0.2mg/kg/day Misoprostol orally for 6 days. The treatment course lasted 6 days for all groups. |
Dosage form | 0.2mg/kg/day for 6 days; p.o. |
Applications | Cardiac damage caused by Doxorubicin was attenuated by Misoprostol treatment. Treatment with Misoprostol decreased significantly serum cardiac troponin-I, brain natriuretic peptide levels, and lactate dehydrogenase, aspartate aminotransferase, alanine transaminase and creatine kinase isoenzyme-MB activities. Misoprostol also decreased NADPH oxidase-4 and caspase-3 levels. |
References: | |
| Cas No. | 59122-46-2 | SDF | |
| Überlieferungen | SC 29333 | ||
| Chemical Name | methyl 7-((1R,2R,3R)-3-hydroxy-2-((E)-4-hydroxy-4-methyloct-1-en-1-yl)-5-oxocyclopentyl)heptanoate | ||
| Canonical SMILES | CCCCC(C/C([H])=C([H])/[C@]1([H])[C@@](C(C[C@@]1([H])O)=O)([H])CCCCCCC(OC)=O)(O)C | ||
| Formula | C22H38O5 | M.Wt | 382.53 |
| Löslichkeit | ≥ 11.05mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6142 mL | 13.0709 mL | 26.1417 mL |
| 5 mM | 522.8 μL | 2.6142 mL | 5.2283 mL |
| 10 mM | 261.4 μL | 1.3071 mL | 2.6142 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)